SciELO - Scientific Electronic Library Online

 
vol.16 número3Mesilato de imatinib como tratamiento de primera línea en pacientes con leucemia mieloide crónica Filadelfia + (LMC-Ph+) en fase acelerada (FA), en comparación con fase crónica (FC)Identificación de los factores de bajo riesgo en el lactante pequeño con fiebre sin foco evidente índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Acta médica Grupo Ángeles

versión impresa ISSN 1870-7203

Resumen

VAZQUEZ MONTANA, Cynthia Anarika; ALARCON RODRIGUEZ, José Jesús  y  LINARES NOLASCO, Filemón. Pharmacoeconomics of sugammadex for the reversal of neuromuscular relaxation under general anaesthesia at Ángeles Pedregal Hospital. Acta méd. Grupo Ángeles [online]. 2018, vol.16, n.3, pp.209-218. ISSN 1870-7203.

Neuromuscular blockers facilitate endotracheal intubation, invasive airway management and transoperative relaxation. Residual neuromuscular blockade is a frequent problem and little detected in the Post-Anesthesia Care Unit. The train of four is a useful method of neuromuscular monitoring. The objective of the study was to perform an economic evaluation of sugammadex versus neostigmine/atropine.

Material and methods:

Observational, prospective study in patients with elective laparoscopic surgery under general anesthesia with rocuronium. Performing neuromuscular reversal in moderate block (TOF < 0.9). Group 1 (n = 30) sugammadex at 2 mg/kg, group 2 (n = 30) neostigmine at 0.04 mg/kg and atropine at 0.15 mg/kg.

Results:

Sugammadex took 1.4 minutes to reach TOFr > 90% and neostigmine 15.42 minutes (p = 0.00), finding time savings in the operating room of 14.01 minutes. In PACU, sugammadex presented average stay time of 52.03 minutes and neostigmine of 68.90 minutes, saving 16.87 minutes (p = 0.0002). The cost savings per fraction of time in the operating room was $ 1,343.5 pesos and in PACU of $ 2,760.50 pesos.

Conclusions:

Sugammadex presents a significant difference in the time saved in the operating room, but not in the cost. Its use in the operating room allows savings in time of stay and cost to discharge from the PACU, compensating the cost of the medication.

Palabras llave : Pharmacoeconomics; neuromuscular reversal; residual neuromuscular block.

        · resumen en Español     · texto en Español     · Español ( pdf )